Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action

    loading  Checking for direct PDF access through Ovid

Abstract

Poly(ADP-ribose) polymerase (PARP) inhibitors are the first DNA damage response targeted agents approved for cancer therapy. Here, we focus on their molecular mechanism of action by PARP “trapping” and what this means for both clinical monotherapy and combination with chemotherapeutic agents.

Related Topics

    loading  Loading Related Articles